Featured Article

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

New guidelines for dyslipidemia management and atherosclerosis prevention include a wider range of disease stages and more aggressive intervention.

Latest Features

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Statins Limit Vaccine Efficacy of Influenza Strain

Statins Limit Vaccine Efficacy of Influenza Strain

Statin use modified vaccine effectiveness and influenza risk for A(H3N2) infection but not for A(H1N1).

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Considering Cardiovascular Risks of Antidiabetic Drugs

Considering Cardiovascular Risks of Antidiabetic Drugs

A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

LATEST NEWS

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

Patients with visit-to-visit variability of fasting plasma glucose may have a higher risk of developing cardiovascular disease and all-cause mortality.

FDA Approves PCSK9 Inhibitor for Stroke, MI Prevention

FDA Approves PCSK9 Inhibitor for Stroke, MI Prevention

The FDA has approved evolocumab for the prevention of heart attacks.

Almonds With or Without Dark Chocolate May Improve Lipid Profiles in Controlled Feeding Conditions

Almonds With or Without Dark Chocolate May Improve Lipid Profiles in Controlled Feeding Conditions

Lipid profiles of overweight people can be improved by eating raw almonds, dark chocolate, and cocoa.

PCSK9 Inhibitor Resistance May Be Identified by Plasma PCSK9

PCSK9 Inhibitor Resistance May Be Identified by Plasma PCSK9

PCSK9 may help assess apparent resistance to PCSK9 inhibitors.

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Evolocumab may decrease the risk for adverse cardiovascular events in patients with and without diabetes.

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

Rates of approval for a PCSK9 inhibitor treatment are low overall.

PCSK9 Inhibitor Does Not Affect Cognitive Function

PCSK9 Inhibitor Does Not Affect Cognitive Function

Evolocumab is not associated with adverse cognitive effects even when low low-density lipoprotein cholesterol levels have been achieved.

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Serum lipid profile changes were shown to occur within the first year of initiating antiretroviral therapy in children.

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Researchers find statins could be a potential treatment option in COPD.

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less than half of patients prescribed PCSK9 inhibitors receive approval, and only about 30% ever receive therapy.

Sign Up for Free e-Newsletters